Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AZ01
- Development stage
- Discontinued
- Lead developer
- Allozyne
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Administration
- Subcutaneous
01
Overview
AZ01 is a PEGylated interferon beta developed by Allozyne for the treatment of multiple sclerosis. It is designed as a long-acting form of interferon beta, utilizing "click chemistry" technology to create a homogeneous, long-acting protein drug. Interferon beta is a cytokine that modulates the immune system and has anti-inflammatory effects, making it a treatment for autoimmune diseases like multiple sclerosis.
- Other names
- PEGylated interferon betalong-acting interferon beta
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on AZ01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AZ01.